ストックスクリーナーアプリを入手
0.00
100.00%
-9.81
前日終値:
$9.81
開ける：
$0
24時間の取引高:
0
Relative Volume:
0.00
時価総額：
$47.48M
収益：
-
当期純損益:
$-168.86M
株価収益率:
0.00
EPS:
-1.68
ネットキャッシュフロー:
$-125.29M
1週間 パフォーマンス:
-100.00%
1か月 パフォーマンス:
-100.00%
6か月 パフォーマンス:
-100.00%
1年 パフォーマンス:
-100.00%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$0.00
$0.00
52週間の値動き範囲:
$0.00
$24.15
Allovir Inc Stock (ALVR) Company Profile
ALVR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALVR
Allovir Inc
|
0.00 | 47.48M | 0 | -168.86M | -125.29M | -1.68 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Allovir Inc Stock (ALVR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-12-26 | ダウングレード | BofA Securities | Buy → Underperform |
| 2023-12-22 | ダウングレード | JP Morgan | Overweight → Underweight |
| 2023-12-22 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2023-12-22 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-08-18 | 開始されました | BofA Securities | Buy |
| 2021-10-19 | 再開されました | Morgan Stanley | Overweight |
| 2020-08-24 | 開始されました | JP Morgan | Overweight |
| 2020-08-24 | 開始されました | Morgan Stanley | Overweight |
| 2020-08-24 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Allovir Inc (ALVR) 最新ニュース
AlloVir ($ALVR) Is Paying a Settlement to Investors — Here’s How to Get Your Share - TradingView
Kalaris Therapeutics, Inc. SEC 10-Q Report - TradingView
Kalaris Eyes Breakthrough in AMD Treatment: Phase 1 Trial Progress and $101M War Chest Revealed in Q1 Earnings - Stock Titan
Shareholders that lost money on AlloVir, Inc.(ALVR) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 19, 2024 in AlloVir LawsuitALVR - ACCESS Newswire
AlloVir, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your RightsALVR - ACCESS Newswire
Lost Money on AlloVir, Inc.(ALVR)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
Shareholders that lost money on AlloVir, Inc.(ALVR) should contact Levi & Korsinsky about pending Class ActionALVR - ACCESS Newswire
Levi & Korsinsky Notifies AlloVir, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineALVR - ACCESS Newswire
Renaissance Technologies LLC Trims Stock Position in AlloVir, Inc. (NASDAQ:ALVR) - Defense World
DEADLINE ALERT: Bernstein Liebhard LLP Reminds AlloVir, Inc. Investors of Upcoming Deadline - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies AlloVir, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineALVR - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Levi & Korsinsky Notifies AlloVir, Inc.(ALVR) Investors of a Class Action Lawsuit and Upcoming Deadline - marketscreener.com
Halper Sadeh LLP, AlloVir, Inc., Avid Bioservices, Inc., EMCORE Corporation - The Bradford Era
Halper Sadeh LLP, Aerovate Therapeutics, Inc., Staffing 360 Solutions, Inc., Allovir - The Bradford Era
AlloVir Announces FDA Clearance of Investigational New Drug Application for ALVR106, an Allogeneic, Off-The-Shelf, Multi-Virus Specific T Cell Therapy Targeting Four Devastating Respiratory Viruses - marketscreener.com
William Blair Initiates Kalaris Therapeutics With Outperform Rating - MarketScreener
(ALVR) Technical Data - news.stocktradersdaily.com
Kalaris Therapeutics appoints new board chair By Investing.com - Investing.com Canada
The Gross Law Firm Notifies Shareholders of AlloVir, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 19, 2024(NASDAQ: ALVR) - MarketScreener
Kalaris Therapeutics appoints new board chair - Investing.com India
Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee - The Manila Times
Kalaris Expands Board Of Directors Appointing Leone Patterson As Chair Of Audit Committee - MarketScreener
Class Action Filed Against AlloVir, Inc. (ALVR) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
ALLOVIR INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options - MarketScreener
ALVR Bronstein, Gewirtz & Grossman LLC Announces that AlloVir Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - MarketScreener
The Law Offices of Vincent Wong Remind AlloVir Investors of a Lead Plaintiff Deadline of March 19, 2024 - MarketScreener
ROSEN, SKILLED INVESTOR COUNSEL, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionALVR - MarketScreener
ALLOVIR SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options - Marketscreener.com
Kalaris Therapeutics’ chief accounting officer sells shares worth $8,135 - Investing.com India
Kalaris Therapeutics’ chief accounting officer sells shares worth $8,135 By Investing.com - Investing.com UK
Trend Tracker for (ALVR) - Stock Traders Daily
Kalaris and AlloVir Inc. complete merger - Ophthalmology Times
Kalaris Therapeutics Announces Closing of Merger With AlloVir - VisionMonday.com
Parainfluenza Virus Infection Market to Expand Significantly by 2034, States DelveInsight Report | Ansun Biopharma, AlloVir, MedImmune - The Globe and Mail
ROSEN, LEADING TRIAL ATTORNEYS, Encourages AlloVir, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class ActionALVR - Marketscreener.com
ALLOVIR, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts against AlloVir, Inc. - Marketscreener.com
ALLOVIR, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) - Marketscreener.com
Kalaris Therapeutics Completes Merger with AlloVir - Marketscreener.com
AlloVir Merges with Kalaris Therapeutics, Inc. - TipRanks
Kalaris Announces Closing of Merger with AlloVir - The Manila Times
Kalaris Therapeutics Completes Merger with AlloVir, Advances Phase 1 Trial of TH103 for Neovascular Retina Diseases - Nasdaq
Allovir Inc (ALVR) 財務データ
収益
当期純利益
現金流量
EPS
1.54%
7.58%
大文字化:
|
ボリューム (24 時間):